A study looking at biomarkers in bladder cancer (Gemtrans)
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
Cancer type:
Status:
Phase:
This study is looking at chemicals and proteins called biomarkers in the blood and urine of people with bladder cancer.
Biomarkers are substances that doctors can measure in the body to help them tell how a disease is developing or how a treatment is working. In this study doctors want to look at biomarkers in people who are having gemcitabine and radiotherapy to treat bladder cancer. They call this combination of treatments GemX.
The aims of this study are
- To find out more about biomarkers in people having GemX
- To learn more about bladder cancer and its treatment
Who can enter
You may be able to enter this study if you are under the care of the Christie Hospital, Manchester and
- You have transitional cell bladder cancer
- Your doctor wants to treat you with gemcitabine and radiotherapy (GemX)
- You have satisfactory blood test results
- You are at least 18 years old
You cannot enter this study if you
- Have had any other cancer, apart from carcinoma in situ of the cervix or non melanoma skin cancer that has been successfully treated
- Have any other illness that is a cause for concern
Trial design
This study will recruit 50 people.
Everyone taking part will give weekly blood and urine samples while they have GemX treatment.
The study team will ask you to fill out a questionnaire at each visit during your treatment, again at 6 weeks and then at each of your yearly follow up visits, for 3 years. The questionnaire will ask about side effects and how you have been feeling. This is called a quality of life study.
If you agree to take part in this study, the researchers will also ask for a sample of tissue taken when you had surgery to diagnose your cancer. If you don’t want to give tissue samples for this study, you don’t have to. You can still take part in the study.
Hospital visits
There are no extra hospital visits if you take part in this study. The researchers will take the study samples when you come to the hospital to see the doctor.
Side effects
The only side effect you may have is a small bruise when the blood sample is taken.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Ananya Choudhury
Supported by
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
The Christie NHS Foundation Trust
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
